retatrutide phase 2 trial new england journal of medicine The MariTide once-monthly maridebart cafraglutide, a peptide–antibody conjugate, showed substantial weight reduction in participants with obesity with or without type 2 diabetes. Full trial results and Research Summary Retatrutide—A Game Changer in Obesity

Meeting BMI Requirements for Prescription Weight Loss Medication FDA-approved GLP-1 medications for weight loss are typically indicated for: Adults with obesity, defined as a body mass index of 30 or higher Adults with overweight, defined as a BMI of 27 or higher, who also have at least one weight-related medical condition A healthcare provider can confirm whether these criteria apply to your situation

It was going to be $1,600 a month

Bariatric surgery leads to significant improvement in glycemic control and metabolic syndrome components through weight loss but benefits for micro/macro vascular complications of diabetes remain unclear

Suitable for smaller-scale laboratory investigations Useful for analytical verification procedures Supports controlled pilot research workflows Allows flexible comparison with other peptide concentrations Facilitates laboratory screening studies Quality & Verification Standards Reliable peptide research depends on analytical consistency, traceability, and verification

What We DONT Know Yet Heres what we DONT have: We have no controlled trials of women deliberately taking GLP-1s during pregnancy (and well never have theseit would be unethical)

Yeast infections most commonly manifest as vulvovaginal candidiasis in women or candidal balanitis in men, though oral thrush and cutaneous candidiasis can also occur